Insider Transactions in Q2 2024 at Regenxbio Inc. (RGNX)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 28
2024
|
Olivier Danos Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,363
+1.07%
|
$12,267
$9.95 P/Share
|
|
May 31
2024
|
Daniel Tasse |
BUY
Grant, award, or other acquisition
|
Direct |
4,790
+29.8%
|
-
|
|
May 31
2024
|
Allan M. Fox |
BUY
Grant, award, or other acquisition
|
Direct |
4,790
+29.8%
|
-
|
|
May 31
2024
|
Jean Bennett |
BUY
Grant, award, or other acquisition
|
Direct |
4,790
+29.8%
|
-
|
|
May 31
2024
|
Alexandra Glucksmann |
BUY
Grant, award, or other acquisition
|
Direct |
4,790
+29.8%
|
-
|
|
May 31
2024
|
Argeris N Karabelas |
BUY
Grant, award, or other acquisition
|
Direct |
4,790
+29.8%
|
-
|
|
May 31
2024
|
George V Migausky |
BUY
Grant, award, or other acquisition
|
Direct |
4,790
+29.8%
|
-
|
|
May 31
2024
|
Jennifer Zachary |
BUY
Grant, award, or other acquisition
|
Direct |
4,790
+25.1%
|
-
|
|
May 31
2024
|
David C Stump |
BUY
Grant, award, or other acquisition
|
Direct |
4,790
+29.8%
|
-
|
|
May 14
2024
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
15,000
-3.55%
|
$225,000
$15.81 P/Share
|
|
May 14
2024
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+3.42%
|
$45,000
$3.76 P/Share
|
|
Apr 15
2024
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
15,000
-3.55%
|
$270,000
$18.19 P/Share
|
|
Apr 15
2024
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+3.42%
|
$45,000
$3.76 P/Share
|